In cancers such as melanoma, breast, head and neck, and lung, a subset of research indicates improved patient survival outcomes, crediting this to efficient antigen presentation, bolstered cytotoxic CD8+ T cell activity, enhanced NK cell recruitment, and a dominant IFN-γ response [18, 19, 20]. The gene discussed is CD8A; the disease is melanoma.